63 related articles for article (PubMed ID: 8648108)
41. Murine marrow coexpressing H2-Dsp2 and H2-Db on host natural killer cell rejection.
Liu J; Sentman CL; Kumar V; Bennett M
Transplantation; 1997 Feb; 63(3):444-9. PubMed ID: 9039937
[TBL] [Abstract][Full Text] [Related]
42. Alteration of the natural killer repertoire in H-2 transgenic mice: specificity of rapid lymphoma cell clearance determined by the H-2 phenotype of the target.
Höglund P; Glas R; Ohlén C; Ljunggren HG; Kärre K
J Exp Med; 1991 Aug; 174(2):327-34. PubMed ID: 1856626
[TBL] [Abstract][Full Text] [Related]
43. Hemopoietic histocompatibility (Hh-1) phenotype and the regulation of its expression.
Kaminsky SG; Yoshida MA; Milisauskas VK; Nakamura I
Immunogenetics; 1992; 35(2):117-25. PubMed ID: 1735558
[TBL] [Abstract][Full Text] [Related]
44. Dd is the only gene that controls NK cell resistance of heterozygous H-2b/d cells.
Zheng WP; Kiura K; Nakamura I
Mol Immunol; 1995 Jul; 32(10):773-6. PubMed ID: 7659101
[No Abstract] [Full Text] [Related]
45. Enumeration of H-2-gene products: failure to detect L molecules in the H-2b haplotype.
Hansen TH; Ozato K; Sachs DH
Ann Immunol (Paris); 1980; 131C(3):327-34. PubMed ID: 7406442
[TBL] [Abstract][Full Text] [Related]
46. Host H-2 genotype regulates the metastatic ability of H-2-associated variants of B16 melanoma: defense systems screening for absence of self H-2 components by natural killer cells and host-associated homing barrier.
Kawano Y; Taniguchi K; Kärre K; Toshitani A; Nomoto K
Cell Immunol; 1988 Feb; 111(2):341-53. PubMed ID: 3338095
[TBL] [Abstract][Full Text] [Related]
47. Immunogenetic studies of H-2 antigens of MCG 3 tumour cells.
Torres MD; Gutiérrez F; Rueda G; Osorio C
Rev Esp Fisiol; 1981 Jun; 37(2):173-6. PubMed ID: 7313274
[TBL] [Abstract][Full Text] [Related]
48. In vivo lysis of L5178Y cells in the establishment of the tumor-dormant state in DBA/2 mice.
Wheelock EF; Weinhold KJ; Ingenito GG; Goldstein LT
J Immunol; 1980 Apr; 124(4):1642-7. PubMed ID: 7365237
[No Abstract] [Full Text] [Related]
49. Immunological cross-reactivity between H-2Dk product and DTIC-treated H-2d lymphoma.
Marelli O; Testorelli C; Canti G; Festenstein H; Nicolin A
J Immunogenet; 1982 Dec; 9(6):407-12. PubMed ID: 6186748
[TBL] [Abstract][Full Text] [Related]
50. SHP-1/immunoreceptor tyrosine-based inhibition motif-independent inhibitory signalling through murine natural killer cell receptor Ly-49A in a transfected B-cell line.
Motoda K; Takata M; Kiura K; Nakamura I; Harada M
Immunology; 2000 Jul; 100(3):370-7. PubMed ID: 10929060
[TBL] [Abstract][Full Text] [Related]
51. Lack of F1 anti-parental resistance in H-2b/d F1 hybrids devoid of beta2-microglobulin.
Höglund P; Olsson-Alheim MY; Johansson M; Kärre K; Sentman CL
Eur J Immunol; 1997 Jan; 27(1):342-5. PubMed ID: 9022038
[TBL] [Abstract][Full Text] [Related]
52. Expression of hemopoietic histocompatibility antigens on H-2-loss variants of F1 hybrid lymphoma cells: evidence consistent with trans gene regulation.
Rembecki RM; Bennett M; Kumar V; Potter TA
J Immunol; 1987 Apr; 138(8):2734-8. PubMed ID: 3549904
[TBL] [Abstract][Full Text] [Related]
53. Murine NK cell allospecificity-1 is defined by inhibitory ligands.
Zheng WP; Kiura K; Milisauskas VK; DeNardin E; Nakamura I
J Immunol; 1996 Jun; 156(12):4651-5. PubMed ID: 8648108
[TBL] [Abstract][Full Text] [Related]
54. The ability of H-2Dd molecule to affect natural resistance to hemopoietic allografts is an intrinsic property shared by Ddm1 but not Ld.
Milisauskas VK; Nakamura I
Eur J Immunol; 1994 Feb; 24(2):336-42. PubMed ID: 8299682
[TBL] [Abstract][Full Text] [Related]
55. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells.
Karlhofer FM; Ribaudo RK; Yokoyama WM
Nature; 1992 Jul; 358(6381):66-70. PubMed ID: 1614533
[TBL] [Abstract][Full Text] [Related]
56. Allospecificities of B6D2F1 hybrid NK cell subsets defined by Ly-49A expression.
Basiri H; Kiura K; DeNardin EG; Nakamura I
J Immunol; 1995 Sep; 155(6):2822-32. PubMed ID: 7673698
[TBL] [Abstract][Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
